Alnylam Pharmaceuticals, Inc. (ALNY)

NMS – Real Time Price. Currency in USD

291.37

-1.80 (-0.61%)

At close: Jun 26, 2026, 4:00 PM EDT

291.14

-0.23 (-0.08%)

After-hours: Jun 26, 2026, 6:19 PM EDT

16.06.2026

Why Alnylam Pharmaceuticals (ALNY) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

12.06.2026

Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum?

Amvuttra's blockbuster growth is reshaping ALNY's revenue mix, and fresh ATTR-CM approvals can unlock an even larger market.

12.06.2026

Alnylam to Host Tenth “RNAi Roundtable” Webcast Series

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 10th series of “RNAi Roundtable” webinars over the coming months. The series will offer presentations from Alnylam scientists and physicians who will review recent progress in a selection of the Company's pipeline programs, as well as medical thought leaders who will provide their perspectives on unmet clinical needs. Each event will b.

10.06.2026

GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region

ATHENS, Greece--(BUSINESS WIRE)--GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region.

10.06.2026

Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

09.06.2026

Alnylam Pharmaceuticals Unveils 2030 Targets, Betting on AMVUTTRA and Pipeline Readouts

Alnylam Pharmaceuticals NASDAQ: ALNY executives outlined the company's 2030 financial targets, TTR franchise strategy and near-term pipeline priorities during a Goldman Sachs event hosted by analyst Salveen Richter.

08.06.2026

Bloom Energy, Astera Labs, Alnylam, Reddit Could Be Among Next Adds to S&P 500

The index added two companies on Friday, but more are likely to be added in the near future.

Videos

19.12.2025

Neutral

This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter

01.08.2025

Positive

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

01.08.2025

Negative

President Trump demands drugmakers slash prices within 60 days

Press releases

10.06.2026

GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region

ATHENS, Greece--(BUSINESS WIRE)--GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region.

03.06.2026

Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics

CAMBRIDGE, Mass. & PALO ALTO, Calif.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Inceptive Nucleics, Inc., which builds foundation models of life, today announced a strategic collaboration agreement to increase the pace of therapeutic innovation. The collaboration is valued at up to $2B with upfront consideration of $30M, including cash and the purchase of Inceptive equity. Inceptive is eligible to receive additional payments based.

19.05.2026

Alnylam Issues 2025 Corporate Responsibility Report

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the publication of its 2025 Corporate Responsibility Report. The 2025 report details how the company is scaling its corporate responsibility efforts in tandem with its business growth. Reflected throughout the report is the global theme, “Accepting Challenges to Improve the Health of Humanity,” which remains central to Alnylam's strategy and is embedded across.

12.05.2026

New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new analyses from the HELIOS-B Phase 3 study of vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM), adding to the growing body of evidence supporting vutrisiran and reinforcing the durability of transthyretin (TTR) knockdown and its well-characterized safety profile. Vutrisiran is the first and.

Alnylam Pharmaceuticals, Inc. (ALNY)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Alnylam Pharmaceuticals, Inc. (ALNY)

Why Alnylam Pharmaceuticals (ALNY) is a Top Momentum Stock for the Long-Term

Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum?

Alnylam to Host Tenth “RNAi Roundtable” Webcast Series

GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region

Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Alnylam Pharmaceuticals Unveils 2030 Targets, Betting on AMVUTTRA and Pipeline Readouts

Bloom Energy, Astera Labs, Alnylam, Reddit Could Be Among Next Adds to S&P 500

Videos

Press releases

GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region

Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics

Alnylam Issues 2025 Corporate Responsibility Report

New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden

Why Alnylam Pharmaceuticals (ALNY) is a Top Momentum Stock for the Long-Term

Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum?

Alnylam to Host Tenth “RNAi Roundtable” Webcast Series

GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region

Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Alnylam Pharmaceuticals Unveils 2030 Targets, Betting on AMVUTTRA and Pipeline Readouts

Bloom Energy, Astera Labs, Alnylam, Reddit Could Be Among Next Adds to S&P 500

Videos

Press releases

GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region

Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics

Alnylam Issues 2025 Corporate Responsibility Report

New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden

Search stocks

Alnylam Pharmaceuticals, Inc. (ALNY)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Alnylam Pharmaceuticals, Inc. (ALNY)

Why Alnylam Pharmaceuticals (ALNY) is a Top Momentum Stock for the Long-Term

Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum?

Alnylam to Host Tenth “RNAi Roundtable” Webcast Series

GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region

Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Alnylam Pharmaceuticals Unveils 2030 Targets, Betting on AMVUTTRA and Pipeline Readouts

Bloom Energy, Astera Labs, Alnylam, Reddit Could Be Among Next Adds to S&P 500

Videos

Press releases

GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region

Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics

Alnylam Issues 2025 Corporate Responsibility Report

New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden

Why Alnylam Pharmaceuticals (ALNY) is a Top Momentum Stock for the Long-Term

Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum?

Alnylam to Host Tenth “RNAi Roundtable” Webcast Series

GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region

Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Alnylam Pharmaceuticals Unveils 2030 Targets, Betting on AMVUTTRA and Pipeline Readouts

Bloom Energy, Astera Labs, Alnylam, Reddit Could Be Among Next Adds to S&P 500

Videos

Press releases

GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region

Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics

Alnylam Issues 2025 Corporate Responsibility Report

New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden